Using Cannabidiol Oil to Prevent Nausea After Surgery
Sublingual Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting in Elective Gynaecological Patients at the University Hospital of the West Indies (UHWI)
This study is testing if Cannabidiol oil can help women feel less nauseous after having elective gynecological surgery compared to a placebo.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | The University of The West Indies Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Kingston) |
| Trial ID | NCT06137027 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Cannabidiol oil in reducing postoperative nausea and vomiting in women undergoing elective gynaecological surgery. Participants will receive either Cannabidiol oil or a placebo sublingually before their procedure, and the incidence of nausea and vomiting will be compared between the two groups in the first 24 hours post-surgery. Additionally, the study will assess pain levels, analgesic requirements, and overall patient satisfaction with the anaesthetic experience. The aim is to determine if Cannabidiol oil can improve recovery outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates are women aged 18-65 undergoing elective gynaecological surgical procedures under general anaesthesia.
Not a fit: Patients with allergies to cannabis products, those with psychological conditions affecting consent, or those undergoing regional anaesthesia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new, effective option for managing postoperative nausea and vomiting, enhancing patient comfort and satisfaction.
How similar studies have performed: While Cannabidiol oil has shown effectiveness in treating chemotherapy-induced nausea, its application for postoperative nausea is less explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All patients for elective gynaecological surgical procedures under general anaesthesia at the Main operating theatre, UHWI between the ages of 18-65 years. Exclusion Criteria: * Reported allergy to cannabis/CBD by products, coconut oil, peppermint oil * Patients \< 18 years * Patients experiencing disease related nausea and vomiting * Patients with psychological/psychiatric illnesses which prevent communication or impairs their ability to give informed consent * Patients undergoing regional anaesthesia * Contraindication to medicinal cannabis such as unstable cardiovascular disease, substance use disorder, or significant mental health disorder * Cannabis use within 30 days of surgery * Pregnancy
Where this trial is running
Kingston
- University Hospital of the West Indies — Kingston, Jamaica (Recruiting)
Study contacts
- Principal investigator: Ingrid Tennant, DM, PhD — University Hospital of the West Indies
- Study coordinator: Vanessa Minott
- Email: vanessa.minott@mymona.uwi.edu
- Phone: 876-455-2780
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.